CENTRAL ILLINOIS PARKINSON SUPPORT GROUP

Blessed are those who can laugh at themselves....

Web site: www.heartstohands.org They shall never cease to be entertained


DATE: July 8, 2017 TIME: 12:00 - 2:00 PM

Program: We will have our annual Picnic Starting at 12:00.

WHERE: CrossFit 309 Rock Steady Boxing.

5629 N Galena Rd,

Peoria Heights, IL 61616



Last Month Dr. Renato DeLosSantos gave a great program on Parkinson's "More Than Motor Symptoms". His talk highlights the issues Hallucinations and Parkinson's and the different options available for dealing with them.

The Don Bohlander Parkinson's FundRACERS partnered with John Austin, David Wisehart, Kevin Tisdale, Cody Strong and Trent Richardson and Carpenter's Local #237, to install a wheelchair ramp for a deserving Parkinson's survivor. Thank You to everyone involved with this project, it is truly outstanding the dedication that everyone has shown to pull this off.







ACADIA®

Pharmaceuticals

CHANGING OVER TO RYTARY FOR PARKINSON'S DISEASE



The main forms of L-dopa have been Sinemet and Madopar in immediate release or controlled release versions. Rytary (in the U.S.) and Numient (in the E.U.) are potentially advantageous over both of these because they include L-dopa and carbidopa and combine the immediate release version of L-dopa and the controlled release

versions of L-dopa. For more information go to Rytary: http://www.rxlist.com/rytary-drug.htm

The average frequency of doses is 3.5 times per day for IPX066 (Rytary or Numient) compared to 2.6 times per day for Controlled Release (CR) versions of their previous form of L-dopa, and 4.6 times per day for Immediate Release (IR) versions of their previous form of L-dopa with it. Those people taking only Controlled Release (CR) versions of their previous form of L-dopa took it an average of 4.7 times per day. Around 43% of people taking IPX066 (Rytary or Numient) were much or very much improved in comparison to their previous treatment. Around 68% of people taking IPX066 (Rytary or Numient) were at least minimally improved in comparison to their previous treatment.

The results suggest that those people using the equivalent of Sinemet CR (Controlled release) with or without Sinemet (Immediate release) can be safely converted to Rytary (or Numient), with less frequent doses of L-dopa dosing, and improved overall clinical benefit.

STATINS AND THE RISK OF PARKINSON'S DISEASE



Statins are drugs used to lower cholesterol levels. The use of statins has been claimed to be associated with a more than doubling of the risk of Parkinson's Disease. However, a lot of previous studies found that statins reduced the risk of Parskinson's Disease, down to an average of 81%, and greatly delayed its onset. Higher cholesterol has been related

to lower occurrence of Parkinson's Disease. The researchers suggests that this previously made it hard to know if the effect of statins was due to the statins or the cholesterol levels. For the first time this study accounted for this factor.

August 5, 2017 1:30 pm Stanzia Weatherford Usui Tibetan reiki level 3 Master Instructor Level 3

